| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b/2 data readout example | STAR-001 (LP-184) Pediatric central nervous system (CNS) cancers including atypical teratoid rhabdoid tumor (ATRT) — combination with spironolactone | Phase 1b/2 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 1b/2 data readout example | STAR-001 (LP-184) Pediatric central nervous system (CNS) cancers including atypical teratoid rhabdoid tumor (ATRT) — combination with spironolactone | Phase 1b/2 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 1b/2 data readout example | STAR-001 (LP-184) Pediatric central nervous system (CNS) cancers including atypical teratoid rhabdoid tumor (ATRT) — combination with spironolactone | Phase 1b/2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Lantern Pharma Inc.$3.6
+0.25 (+7.46%)
C 50Pipeline Score Undervalued Pharma · Clinical
Market Cap
39.57 M
EPS
-1.45
P/E Ratio
-
Value Trade
655.09 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.72 M
Operating CF
-3.77 M
Total Assets
7.22 M
Total Liabilities
3.78 M
Equity
3.45 M
D/E Ratio
12,345
6.38 %
Week
28.68 %
1 Month
27.74 %
3 Month
16.67 %
6 Month
-75.85 %
5 Year
-76.35 %
All Time
Cash Data
Cash Position
6.32 M
Monthly Burn
1.26 M
Runway
3.1 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
175.44 K
52 Week Range
1.11 - 5.74
% held by Insiders
24.41 %
% held by Institutions
9.66 %
Enterprise Value
33.30 M
Total Shares
11.30 M
Short %
12.81 %
Float Shares
7.25 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lantern Pharma Inc.
234Total events
3Upcoming
28Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 3
Event history 231
Jun 2, 2026
◆Oral PresentationLP-300Presentation
Presentation of HARMONIC trial data at ASCO 2026
EGFR Exon 21 L858R-mutant non-small cell lung cancersource ↗
Jun 2, 2026
▲Protocol AmendmentLP-300Trial
FDA-cleared protocol amendment extending LP-300 dosing from six to eight cycles
EGFR Exon 21 L858R-mutant non-small cell lung cancersource ↗
Jun 2, 2026
◆Enrollment UpdateLP-300Trial
Enrollment concentrated on L858R subgroup; additional data expected as cohort matures
EGFR Exon 21 L858R-mutant non-small cell lung cancersource ↗
May 21, 2026
●Oral PresentationLP-300Presentation
Rodman & Renshaw fireside chat with Dr. Joseph Treat on never-smoker lung cancer
never-smoker NSCLC adenocarcinomasource ↗
May 19, 2026
▲Type C MeetingLP-300FDA Meeting
FDA Type C meeting request successful; no objections to proposed protocol amendments
never-smoker NSCLC adenocarcinomasource ↗
May 19, 2026
▲Protocol AmendmentLP-300Trial
Protocol amendment to focus enrollment on EGFR exon 21 L858R, transition to single-arm, extend LP-300 dosing to 8 cycles
never-smoker NSCLC adenocarcinomasource ↗
May 15, 2026
May 14, 2026
▼Equity OfferingCorporate
Up to $9.25 million registered direct offering with existing holders and institutional investor
May 2026
▲Type C MeetingLP-300FDA Meeting
Successful Type C meeting outcome with FDA for HARMONIC trial protocol amendments
non-small cell lung cancer (NSCLC) adenocarcinoma in never-smokerssource ↗
Apr 20, 2026
▲Topline ReadoutLP-300Clinical Data
Emerging data shows 8.3-month median PFS in EGFR L858R lung cancer after targeted therapy failure
EGFR L858R lung cancersource ↗
Drug Pipeline Intelligence
C50
Pipeline Score $188M
Pipeline ValueUndervalued
Valuation Signal4
Drugs Scored4.7x
rNPV / MCap Top 75%
Micro Cap (rank 229 of 912)
Percentile RankLantern Pharma Inc. carries a moderate pipeline score (50/100), with $7.0B risk-adjusted pipeline value, led by BNP7787 in Breast Neoplasms (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BNP7787 Small molecule | Breast Neoplasms | Phase 3 | NCT00039780 | 46% | $5.1B | COMPLETED | 764 | - | - | Sep 1, 2014 | - | Jul 13, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LP-300 | EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) | Phase 2 | 2026-06-02 | median PFS: 8.9 months; overall L858R cohort median PFS: 8.4 months; hazard ratio: 0.37; clinical benefit rate: 77%; durable responses: beyond two years Read More | Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer Read More | |
LP-300 | EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) | Phase 2 | 2026-06-02 | median PFS: 8.9 months; overall L858R cohort median PFS: 8.4 months; hazard ratio: 0.37; clinical benefit rate: 77%; durable responses: beyond two years Read More | Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer Read More | |
LP-300 | EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) | Phase 2 | 2026-06-02 | median PFS: 8.9 months; overall L858R cohort median PFS: 8.4 months; hazard ratio: 0.37; clinical benefit rate: 77%; durable responses: beyond two years Read More | Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LTRN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LTRN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LTRN▼ -13.2%on this news
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
Lantern Pharma has launched ZetaOmics, an autonomous computational biology module designed to enhance bioinformatics and multi-omic analysis for all cancer types. This innovative tool is particularly focused on addressing the needs of rare and pediatric cancers. The introduction of ZetaOmics marks a significant advancement in the company's AI-driven precision oncology efforts.
Read more →LTRNLantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Lantern Pharma reported promising data from its Phase 2 HARMONIC™ trial for LP-300 in patients with EGFR Exon 21 L858R-mutant NSCLC. The trial indicates that progression-free survival improves with longer treatment durations, with a median PFS of 8.9 months for patients receiving up to six cycles. The safety profile remains favorable, supporting an extension of treatment cycles from six to eight.
Read more →LTRNLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Lantern Pharma has announced a successful outcome from its FDA Type C meeting regarding the HARMONIC™ Phase 2 trial of LP-300. This trial specifically targets never-smokers diagnosed with non-small cell lung cancer (NSCLC). The positive feedback from the FDA is a significant step forward for the company's development plans.
Read more →LTRNLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-A
Lantern Pharma reported a 27% reduction in net loss year-over-year for Q1 2026 and emphasized capital-efficient operations. The company advanced multiple clinical programs, including successful FDA interactions, while simultaneously launching its AI platform, withZeta.ai. Financially, Lantern strengthened its balance sheet with $9.25 million in financing and plans to create a separate entity for its AI assets. The HARMONIC trial for LP-300 is ongoing, targeting specific patient populations in multiple countries and has shown promising early safety data.
Read more →LTRN▲ +24.7%on this newsshared move
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor $4.4 million upfront with up to an additional $4.85 million of potential aggregate gr
Lantern Pharma Inc. announced a registered direct offering that could raise up to $9.25 million, which includes a $4.4 million upfront payment and potential additional funds through the exercise of warrants. Concurrently, the company plans to establish a separate business entity focused on its AI platform, aimed at enhancing its fundraising efforts. The closing of the offering is expected around May 14, 2026, pending customary conditions. Investors have expressed optimism regarding the company's AI capabilities, though there are risks related to the exercise of warrants and the success of product development.
Read more →LTRNLantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
Lantern Pharma Inc. will report its first quarter 2026 operating and financial results on May 15, 2026. The report will include financial results for the quarter ending March 31, 2026, along with updates on clinical trials and the development of the company's AI platforms. Lantern Pharma focuses on precision oncology therapies using AI and machine learning.
Read more →LTRNLantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
Lantern Pharma has announced a new development roadmap for its withZeta.ai platform, which is designed to enhance oncology research and drug discovery through AI. The roadmap includes the introduction of two major components: ZetaSwarm™, a multi-agent swarm intelligence layer, and ZetaOmics™, a computational biology toolkit. These advancements aim to improve the efficiency and effectiveness of drug discovery processes.
Read more →LTRN▼ -11.6%on this news
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
Lantern Pharma has announced the evolution of its predictBBB.ai platform into a Large Quantitative Model (LQM), providing real-time molecular intelligence accessible via a web interface. This advancement enables pharmaceutical scientists and medicinal chemists to enhance their drug development processes. The LQM aims to improve precision oncology efforts globally.
Read more →LTRN▲ +10.8%on this news
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
Lantern Pharma's investigational drug LP-300 has shown promising results, demonstrating an 8.3-month median progression-free survival in patients with EGFR L858R lung cancer after failure of targeted therapy. Notably, the treatment did not introduce any additional toxicity, suggesting a favorable safety profile. This emerging data could represent a significant advancement in the treatment of this specific lung cancer type.
Read more →LTRNLantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
Lantern Pharma has launched withZeta.ai, an innovative multi-agentic AI co-scientist aimed at advancing drug discovery and development for rare cancers. Subscriptions for the platform are now open, with debut events scheduled at Nasdaq MarketSite on April 16 and at AACR 2026 from April 17 to April 22. This launch represents a significant step forward in leveraging AI technology within the biopharma sector.
Read more →LTRN▲ +10.3%on this news· ran to +45% by day 3
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization
Lantern Pharma Inc. announced its fourth quarter and full year 2025 financial results, highlighting significant operational achievements and advancements in its clinical pipeline. The company achieved clinical validations and received FDA IND clearance for its pediatric CNS cancer trial. Despite positive developments, there are regulatory challenges ahead, particularly concerning proposed amendments to its ongoing HARMONIC trial. Lantern is also expanding its AI capabilities with the launch of an AI Center of Excellence in India.
Read more →LTRN▼ -46.4%on this newsshared move
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
Lantern Pharma and Starlight Therapeutics have received FDA clearance for an Investigational New Drug application for STAR-001, a precision oncology compound. The planned Phase 1 trial will evaluate STAR-001 as a monotherapy and in combination with spironolactone for pediatric patients with relapsed or refractory CNS malignancies. This trial aims to address the significant unmet medical need in pediatric neuro-oncology, particularly for aggressive CNS tumors.
Read more →LTRNLantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
Lantern Pharma Inc. will host a webcast on March 30, 2026, to discuss its fourth quarter and fiscal year 2025 financial results. CEO Panna Sharma will lead the discussion, which will cover operational performance and future milestones in the development of its AI platform, RADR®. The company emphasizes its focus on cancer therapies and the importance of investor engagement.
Read more →LTRNLantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
Lantern Pharma Inc. will present at the 7th Glioblastoma Drug Development Summit in Boston from February 17-19, 2026. CEO Panna Sharma will discuss the application of their AI platform, RADR®, in addressing challenges in treating aggressive brain cancers. The company is focused on developing therapies for CNS cancers, including recurrent glioblastoma.
Read more →LTRNLantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
Lantern Pharma has received FDA Orphan Drug Designation for LP-284, aimed at treating soft tissue sarcomas. This designation adds to its previous approvals for hematologic malignancies, highlighting LP-284's potential in solid tumors. The drug targets DNA repair deficiencies, addressing a significant unmet need in adult oncology, particularly for patients with limited treatment options.
Read more →LTRNLantern Pharma’s LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
Lantern Pharma's LP-284 has received FDA Orphan Drug Designation for treating soft tissue sarcomas, marking its third such designation. This expands the drug's potential beyond hematologic malignancies into solid tumors, addressing a significant unmet need in adult patients. The designation highlights the drug's synthetic lethal mechanism targeting DNA repair deficiencies, which aligns with the characteristics of adult soft tissue sarcomas.
Read more →LTRNLantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Laun
Lantern Pharma has reported strong third-quarter results for 2025, highlighting significant milestones in their clinical program and regulatory advancements. Their LP-184 Phase 1a trial has achieved all primary endpoints, showing a 48% clinical benefit rate among cancer patients with specific mutations. Additionally, a recent FDA Type C meeting affirmed the clinical trial design for a pediatric CNS cancer program while confirming a combination treatment strategy. The company demonstrated continued momentum in their AI-driven platform, further positioning themselves for growth in oncology markets.
Read more →LTRN▲ +7%on this news
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial , with 65 patients enrolled across a
Lantern Pharma reported its second quarter 2025 financial results, highlighting major advancements in its clinical trials. Successful enrollment of 65 patients in the LP-184 Phase 1a trial was achieved, paving the way for further Phase 1b/2 studies targeting recurrent triple negative breast cancer and bladder cancer. The company also reported complete responses in patients from its HARMONIC trial, indicating the efficacy of its drug candidates. Additionally, Lantern maintains strong financial stability, essential for continuing its operational and clinical advancements.
Read more →LTRNLantern Pharma Reports First Quarter 2025 Financial Results and Business Updates Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025 . A
Lantern Pharma Inc. (LTRN) announced its first quarter 2025 financial results, stating the completion of LP-184 Phase 1a clinical trial enrollment, expected by June 2025. The company also reported positive early data from ongoing trials, notably for LP-300 in never-smokers with NSCLC. Lantern emphasized advancements in its AI-driven RADR platform and financial stability with significant cash reserves. Additionally, Future clinical trials are planned for LP-184 in various cancer indications, showing a commitment to addressing unmet patient needs.
Read more →LTRNLantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results HARMONIC trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker N
Lantern Pharma reported strong financial results for Q4 and year-end 2024, alongside significant updates on its drug development pipeline. The HARMONIC trial for LP-300 demonstrated an 86% clinical benefit rate and a 43% objective response rate in never-smoker NSCLC patients. The company obtained FDA Fast Track Designations for LP-184, enhancing its market potential in cancers with high unmet need. Furthermore, the RADR AI platform continues to advance precision oncology, showcasing the company’s commitment to utilizing technology in drug development.
Read more →LTRNLantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating add
Lantern Pharma Inc. reported its third quarter 2024 financial results, highlighting advancements in its AI-guided oncology pipeline. Key updates include promising progress in the Harmonic trial for LP-300 and the Fast Track Designation for LP-184 in glioblastoma. The company aims to leverage its RADR AI platform to develop targeted cancer therapies more efficiently. Lantern is also strategically expanding its clinical trials into Asian markets to target specific patient populations.
Read more →LTRNLantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for developmen
Lantern Pharma reported significant developments during the second quarter of 2024, including an 86% clinical benefit rate from the LP-300 trial's initial patient cohort. The company also received a patent for its drug candidate LP-284 and continues to advance Phase 1 clinical trials for LP-184 and LP-284 without dose-limiting toxicities. Despite a decrease in cash reserves and a net loss of approximately $4.96 million, Lantern initiated a collaboration with Oregon Therapeutics to expedite the development of a new drug candidate. New diagnostic tools for LP-184 are expected to enhance patient selection in future oncology trials.
Read more →LTRN▲ +5.1%on this news
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second
Lantern Pharma Inc. reported its financial results for the first quarter of 2024, highlighting advancements in multiple clinical trials and the progress of its AI platform. The company aims for data readouts for its drug candidate, LP-184, by late summer or early fall, particularly focusing on DDR deficient tumors. Despite the positive operational progress, Lantern posted a net loss of approximately $5.4 million, reflecting increased R&D expenses driven by trial activities. Overall, the market potential for their drug candidates remains substantial, fueling optimism for future developments.
Read more →LTRN▲ +14.5%on this news
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-1
Lantern Pharma (NASDAQ: LTRN) announced its financial results for the fourth quarter and fiscal year 2023, highlighting significant progress in its oncology drug development programs. The company is actively conducting multiple clinical trials across three AI-guided drug candidates, with initial data expected for LP-184 in late 2024. Lantern has achieved substantial growth in its proprietary RADR AI platform, exceeding its 2023 goals for data points and setting ambitious targets for 2024. The firm's expansion into international markets for its clinical trials and the establishment of a subsidiary focused on CNS cancers demonstrate its commitment to innovative cancer therapies.
Read more →LTRNLantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights Received IND clearance from FDA to initiate Phase 1 clinical trial for LP-284 , a first-in-human trial for advanced, refractory non-H
Lantern Pharma (NASDAQ: LTRN) announced its third quarter 2023 financial results, highlighting significant operational achievements, including FDA clearance to initiate a Phase 1 clinical trial for LP-284, aimed at treating advanced non-Hodgkin's lymphomas. The company also dosed its first patient in a Phase 1 trial for LP-184, targeting various advanced solid tumors. Lantern is expanding its Phase 2 LP-300 trial to East Asian countries, where a notable portion of lung cancer cases arise in never-smokers. With a strong cash position, Lantern aims to maintain progress in its clinical programs and leverage its AI platform, RADR, for future developments.
Read more →LTRNLantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights Obtained FDA clearance of the IND application for LP-184 and activated initial clinical sites for the Phase 1 basket trial in relaps
Lantern Pharma reported strong operational highlights and financial results for Q2 2023, marked by the FDA's clearance of the IND application for LP-184 and the activation of clinical sites for a Phase 1 trial. The company has made significant advancements in its drug pipeline, including IND-enabling studies for LP-284 expected to be submitted in August and ongoing recruitment for the Phase 2 Harmonic trial in NSCLC. Lantern's RADR platform continues to evolve, aiming to transform oncology drug development with AI-driven insights and collaborations, including an initiative with Bielefeld University focused on antibody drug conjugates.
Read more →LTRN▲ +5.7%on this news
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights Dosed first patient in the Phase 2 Harmonic clinical trial; a study for the unique population of non-small lung cancer patients who a
Lantern Pharma reported its first quarter 2023 financial results and announced key operational milestones. The company successfully dosed its first patient in the Phase 2 Harmonic clinical trial for non-small cell lung cancer targeting never-smokers. Additionally, Lantern anticipates submitting an IND application for LP-184 to the FDA and aims to launch Phase 1 trials for two new drug candidates in 2023. The company continues to leverage its AI platform RADR to streamline drug development and improve the speed and cost of bringing therapies to market.
Read more →LTRNLantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights The Harmonic clinical trial, a Phase 2 study in never-smoker patients with non-small lung cancer, has activated 5 cl
Lantern Pharma has reported positive operational highlights and financial results for Q4 and fiscal year 2022. The company has activated five clinical trial sites for its Harmonic clinical trial targeting never-smokers with non-small cell lung cancer, with first patient enrollment expected in Q2 2023. Lantern also plans to submit IND applications for LP-184 and LP-284 in mid-2023, with the latter receiving Orphan Drug Designation for treating mantle cell lymphoma. The firm possesses a strong cash position, with projections extending into 2025, and aims to leverage AI technologies for oncology drug development.
Read more →LTRNLantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET
DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timelin
Read more →LTRNLantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights The Harmonic clinical trial activated the first two clinical trial sites for a Phase 2 study in never-smoker patients with non-small
Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights The Harmonic clinical trial activated the first two clinical trial sites for a Phase 2 study in never-smoker patients with non-small lung cancer and anticipates multiple additional sites in the US d
Read more →LTRNLantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights Lantern has launched the Phase 2 clinical trial, Harmonic , for LP-300. The Harmonic clinical trial is focused on never smokers with
Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights Lantern has launched the Phase 2 clinical trial, Harmonic , for LP-300. The Harmonic clinical trial is focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patie
Read more →LTRN▲ +5%on this news
Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights RADR , Lantern's proprietary A.I. and machine learning platform, has now surpassed 20 billion data points, enhancing its precision, i
Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") and machine learning (ML) platform
Read more →LTRNLantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors DALLAS
Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors DALLAS, April 26, 2022/PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial
Read more →LTRNLantern Pharma Announces Extension of Existing Share Repurchase Program DALLAS
Lantern Pharma Announces Extension of Existing Share Repurchase Program 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") and machine learning (ML) platform to transfo
Read more →LTRNLantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights RADR , Lantern's proprietary A.I. and machine learning platform, grew from 1.2 billion to over 18 billion data point
Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights March 10, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") and machine
Read more →LTRNLantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervou
Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System DALLAS, January 24, 2022 /PRNewswire/ -- Lantern
Read more →LTRNLantern Pharma Announces Share Repurchase Program DALLAS
Pharma Announces Share Repurchase Program DALLAS, November 22, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the
Read more →LTRNLantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights - RADR A.I. platform surpasses 10 billion datapoints, significantly enhancing speed and scope of new drug development and expanding pot
Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights DALLAS, November 1, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to tran
Read more →LTRNLantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights Obtained positive preclinical data in pancreatic cancer showing a significant reduction, averaging 93%, in tumor volume in in-vivo a
Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights DALLAS, TX - July 29, 2021 - Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern"), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform
Read more →LTRNLantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights RADR A.I. platform surpasses 4.6 billion datapoints curated for oncology drug development across a wide a range of tumors and drug cl
Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights DALLAS, TX - May 3, 2021 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform o
Read more →LTRNLantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights RADR artificial intelligence ("A.I.") platform surpassed 1.2 billion datapoints Advanced opportunities for LP-184 in gl
Lantern Pharma Reports Fourth Quarter and Financial Results and Operational Highlights DALLAS, TX - March 10, 2021 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transfor
Read more →LTRNLantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress Surpassed One Billion Curated Data Points Powering Company's Proprietary A.I. Platform, RADR , for Cancer Drug Development Adva
Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress DALLAS, TX - October 29, 2020 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform, RADR , to transf
Read more →LTRNAMENDED AND RESTATED LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN I. GENERAL PROVISIONS 1.1 Establishment . On
AMENDED AND RESTATED LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN Establishment. On August 29, 2018, the Board of Directors of Lantern Pharma Inc. adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan. The Lantern Pharma Inc. 2018 Equity Incentive Plan was approved by t
Read more →LTRNLantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress Closed Initial Public Offering Raising Gross Proceeds of $26.3 Million Surpassed 500 Million Curated Oncology Data Points for
Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress Initial Public Offering Raising Gross Proceeds of $26.3 Million 500 Million Curated Oncology Data Points for Company's RADR A.I. Platform Manufacturing Capabilities for LP-300 and LP-184 Tria
Read more →LTRNLantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR , Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction
The machine learning-powered RADR® platform identifies genomically distinct cancer subtypes, and patient groups, that can respond to specific drugs that Lantern and its partners are developing The growing A.I. platform will be pivotal in uncovering combination therapies using La
Read more →LTRNLantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting
DALLAS, June 17, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that w
Read more →LTRNMonday
Monday, June 15, 2020 Lantern Pharma Announces Closing of Initial Public Offering DALLAS, TX / June 15, 2020 / Lantern Pharma Inc. (LTRN) (the "Company"), a clinical stage biotechnology company, focused on leveraging artificial intelligence ("A.I."), machine learning and gen
Read more →LTRNLantern Pharma Announces Closing of Initial Public Offering
DALLAS, June 15, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the p
Read more →LTRNLantern Pharma Announces Pricing of Initial Public Offering
DALLAS, June 10, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients
Read more →LTRNLantern Pharma Appoints David Margrave as Chief Financial Officer and Kishor Bhatia, Ph.D., as Chief Scientific Officer
DALLAS and KEARNY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, announced today the appointment of David Margrave as Chief Financial Officer and Kishor Gopaldas Bhatia, Ph.D., as Chief Scientific Officer. Co
Read more →LTRNLantern Pharma Expands and Strengthens Board of Directors with Healthcare and Pharma Industry Veterans Franklyn Prendergast, MD, Ph.D. and Vijay Chandru, Ph.D.
DALLAS and KEARNY, N.J., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, announced today the appointment of two new members, Franklyn Prendergast, MD, Ph.D. and Vijay Chandru, Ph.D. to its board of directors. In addi
Read more →LTRNLantern Pharma CEO Panna Sharma to Present & Participate in Panel Discussion at AI Applications in Biopharma Summit 2019 in Boston
DALLAS and KEARNY, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI, machine learning (ML) and genomics, today announced its Chief Executive Officer, Panna Sharma, will serve as a speaker and panel participant at the upcoming
Read more →LTRNLantern Pharma Selects Reprocell Inc. to Provide Preclinical Screening and Biomarker Discovery Services for Portfolio of Targeted Oncology Drugs
DALLAS and KEARNY, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging A.I., machine learning (ML) and genomics, announced today that it has selected Reprocell to provide preclinical screening and drug sensitivity work for its port
Read more →LTRNLantern Pharma CEO Panna Sharma to Speak at Bio Data World West 2019
DALLAS and KEARNY, N.J., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, today announced its Chief Executive Officer, Panna Sharma, will present at the 3rd Annual Bio Data World West 2019 in San Diego, CA. Sharma wi
Read more →LTRNLantern Pharma and National Cancer Institute Partner to Aid Precision Oncology Research and Treatments
DALLAS and KEARNY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, today announced a collaboration agreement with the Developmental Therapeutics Branch (DTB) of the National Cancer Institute (NCI) to identify g
Read more →LTRNLantern Pharma CEO Panna Sharma to Showcase AI Platform at Drug Repositioning, Repurposing and Rescue Conference
Presentation to highlight use of machine learning, genomics and AI in building Lantern's oncology drug portfolio and in developing insights about biological mechanisms, biomarker signatures and patient stratification strategies. DALLAS and KEARNY, N.J., Sept. 18, 2019 (GLOBE NEW
Read more →Competitive Position
How LTRN ranks across every disease it competes inCompetitive Position is a premium feature
See how LTRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial